Drugmaker | featured news

Germany drug company Bayer AG says it intends to buy California-based Conceptus to expand its birth control offerings. Bayer said Monday it would launch a pupublicblic offer to pay $31.00 per share for all the stock in Conceptus, Inc. That means Bayer would pay $1.1 billion. Conceptus makes Essure, an irreversible birth control method in which metal and polyester coils are inserted to block a woman's fallopian tubes. The procedure can be done in 10 minutes a doctor's office.

For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup. The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best.

...These recent quality lapses at big drug companies show that contamination and shoddy practices extend well beyond the loosely regulated compounding pharmacies that have attracted attention because of their link to an outbreak of meningitis... [S]everal industry observers and former plant employees said that the recent quality issues were troubling and that manufacturers had been reluctant to fix problems because stopping production was simply too costly in a business where profits were driven by volume.

GlaxoSmithKline is expected to announce a deal to buy Human Genome Sciences for about $2.8 billion as soon as Monday, ending a three-month hostile pursuit of the U.S. biotech company on friendly terms after sweetening its offer.

British drugmaker GlaxoSmithKline will pay $3 billion in fines - the largest health care fraud settlement in U.S. history - for criminal and civil violations involving 10 drugs that are taken by millions of people. The Justice Department said Monday that GlaxoSmithKline PLC will plead guilty to promoting popular antidepressants Paxil and Wellbutrin for unapproved uses. The company also will plead guilty to failing to report to the government for seven years some safety problems with diabetes drug Avandia, which was restricted in the U.S. and banned in Europe after it was found in 2007 to sharply increase the risks of heart attacks and congestive heart failure.

GlaxoSmithKline Plc plans to launch a campaign to replace the entire board of Human Genome Sciences Inc with its own nominees, stepping up its $2.6 billion hostile bid for the U.S. biotech company, sources familiar with the situation said on Wednesday.

British drugmaker GlaxoSmithKline said Wednesday it will no longer wait for Human Genome Sciences to consider an acquisition offer and instead appealed directly to the Rockville firm’s shareholders to accept its $13-per-share asking price.

Officials at drugmaker Merck & Co. say they will take more time to decide what to do about an experimental blood thinner that gave disappointing results in a second big study....

Watson Pharmaceuticals Inc is close to buying Swiss-based Actavis for around $7 billion, marking the latest deal between generics companies racing to achieve economies of scale, three sources familiar with the matter said.

Merck & Co will pay roughly $950 million to settle criminal and civil charges that it promoted the painkiller drug Vioxx for an unapproved use, the U.S. Justice Department said on Tuesday.